Neurotrophic Factors As Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 25

PMID 36835277

Authors

Yousra El Ouaamari

Jasper Van den Bos

Barbara Willekens

Nathalie Cools

Inez Wens

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), spinal cord injury (SCI), and amyotrophic lateral sclerosis (ALS), are characterized by acute or chronic progressive loss of one or several neuronal subtypes. However, despite their increasing prevalence, little progress has been made in successfully treating these diseases. Research has recently focused on neurotrophic factors (NTFs) as potential regenerative therapy for neurodegenerative diseases. Here, we discuss the current state of knowledge, challenges, and future perspectives of NTFs with a direct regenerative effect in chronic inflammatory and degenerative disorders. Various systems for delivery of NTFs, such as stem and immune cells, viral vectors, and biomaterials, have been applied to deliver exogenous NTFs to the central nervous system, with promising results. The challenges that currently need to be overcome include the amount of NTFs delivered, the invasiveness of the delivery route, the blood-brain barrier permeability, and the occurrence of side effects. Nevertheless, it is important to continue research and develop standards for clinical applications. In addition to the use of single NTFs, the complexity of chronic inflammatory and degenerative diseases may require combination therapies targeting multiple pathways or other possibilities using smaller molecules, such as NTF mimetics, for effective treatment.

Citing Articles

Reactive Astrocytes Release GDNF to Promote Brain Recovery and Neuronal Survival Following Ischemic Stroke.

Zhang Z, Zhang N, Ding S Neurochem Res. 2025; 50(2):117.

PMID: 40085335 DOI: 10.1007/s11064-025-04370-6.

Hydrogels for Peripheral Nerve Repair: Emerging Materials and Therapeutic Applications.

Taisescu O, Dinescu V, Rotaru-Zavaleanu A, Gresita A, Hadjiargyrou M Gels. 2025; 11(2).

PMID: 39996669 PMC: 11855328. DOI: 10.3390/gels11020126.

Targeting the sigma-1 receptor with pridopidine induces functional neurorestoration in spinal cord ischemia-reperfusion injury.

Sweed E, Khodir S, Motawea S, El-Haron H, Mostafa B, Elkholy M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39937253 DOI: 10.1007/s00210-025-03851-3.

Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions.

Belenichev I, Popazova O, Bukhtiyarova N, Ryzhenko V, Pavlov S, Suprun E Antioxidants (Basel). 2025; 14(1).

PMID: 39857442 PMC: 11760872. DOI: 10.3390/antiox14010108.

Assessment of the level of apoptosis in differentiated pseudo-neuronal cells derived from neural stem cells under the influence of various inducers.

Naghshbandieh A, Naghshbandieh A, Barfi E, Abkhooie L Am J Stem Cells. 2025; 13(6):250-270.

PMID: 39850017 PMC: 11751472. DOI: 10.62347/BPTG6174.

References

Delivanoglou N, Boziki M, Theotokis P, Kesidou E, Touloumi O, Dafi N . Spatio-temporal expression profile of NGF and the two-receptor system, TrkA and p75NTR, in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2020; 17(1):41. PMC: 6990493. DOI: 10.1186/s12974-020-1708-9. View

Beauverd M, Mitchell J, Wokke J, Borasio G . Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012; 11:CD002064. DOI: 10.1002/14651858.CD002064.pub3. View

Ji W, Li M, Jiang W, Ma X, Li J . Protective effect of brain-derived neurotrophic factor and neurotrophin-3 overexpression by adipose-derived stem cells combined with silk fibroin/chitosan scaffold in spinal cord injury. Neurol Res. 2020; 42(5):361-371. DOI: 10.1080/01616412.2020.1735819. View

Lapchak P, Miller P, Collins F, Jiao S . Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience. 1997; 78(1):61-72. DOI: 10.1016/s0306-4522(97)83045-x. View

Blesch A . Neurotrophic factors in neurodegeneration. Brain Pathol. 2006; 16(4):295-303. PMC: 8095767. DOI: 10.1111/j.1750-3639.2006.00036.x. View

Pollock K, Dahlenburg H, Nelson H, Fink K, Cary W, Hendrix K . Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016; 24(5):965-77. PMC: 4881765. DOI: 10.1038/mt.2016.12. View

Cannella B, Pitt D, Capello E, Raine C . Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am J Pathol. 2000; 157(3):933-43. PMC: 1885703. DOI: 10.1016/S0002-9440(10)64606-8. View

Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt G . Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol. 2003; 461(2):250-61. DOI: 10.1002/cne.10689. View

Gardner A, Lee S, Woods E, Acharya A . Biomaterials-based modulation of the immune system. Biomed Res Int. 2013; 2013:732182. PMC: 3793288. DOI: 10.1155/2013/732182. View

10.

He Z, Zang H, Zhu L, Huang K, Yi T, Zhang S . An anti-inflammatory peptide and brain-derived neurotrophic factor-modified hyaluronan-methylcellulose hydrogel promotes nerve regeneration in rats with spinal cord injury. Int J Nanomedicine. 2019; 14:721-732. PMC: 6342221. DOI: 10.2147/IJN.S187854. View

11.

Uberti F, Morsanuto V, Ghirlanda S, Ruga S, Clemente N, Boieri C . Highly Diluted Acetylcholine Promotes Wound Repair in an Model. Adv Wound Care (New Rochelle). 2018; 7(4):121-133. PMC: 5905879. DOI: 10.1089/wound.2017.0766. View

12.

Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C . Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A. 2002; 99(4):2258-63. PMC: 122352. DOI: 10.1073/pnas.042693799. View

13.

Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B . Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998; 9(5):246-57. DOI: 10.1159/000017069. View

14.

Weissmiller A, Wu C . Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012; 1(1):14. PMC: 3542569. DOI: 10.1186/2047-9158-1-14. View

15.

Lauria G, Bella E, Antonini G, Borghero G, Capasso M, Caponnetto C . Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry. 2015; 86(8):879-86. PMC: 4515982. DOI: 10.1136/jnnp-2014-308996. View

16.

Pardridge W . Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol. 2003; 513:397-430. DOI: 10.1007/978-1-4615-0123-7_15. View

17.

Bongioanni P, Reali C, Sogos V . Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2004; (3):CD004302. PMC: 8078584. DOI: 10.1002/14651858.CD004302.pub2. View

18.

Lepore A, Haenggeli C, Gasmi M, Bishop K, Bartus R, Maragakis N . Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007; 1185:256-65. PMC: 2265207. DOI: 10.1016/j.brainres.2007.09.034. View

19.

Carelli S, Giallongo T, Gombalova Z, Merli D, Di Giulio A, Gorio A . EPO-releasing neural precursor cells promote axonal regeneration and recovery of function in spinal cord traumatic injury. Restor Neurol Neurosci. 2017; 35(6):583-599. PMC: 5701768. DOI: 10.3233/RNN-170750. View

20.

Tuszynski M, Thal L, Pay M, Salmon D, U H, Bakay R . A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005; 11(5):551-5. DOI: 10.1038/nm1239. View